Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 27, Pages E5352-E5361
Publisher
Proceedings of the National Academy of Sciences
Online
2017-07-04
DOI
10.1073/pnas.1703071114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins
- (2016) Lisa M. Nilsson et al. CANCER RESEARCH
- Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
- (2016) Wei Liu et al. Cell Host & Microbe
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression
- (2016) Shwu-Yuan Wu et al. Cell Reports
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase
- (2015) Jaya Sangodkar et al. FEBS Journal
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Quantitative proteomics using SILAC: Principles, applications, and developments
- (2015) Xiulan Chen et al. PROTEOMICS
- Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
- (2015) H. Ogiwara et al. Cancer Discovery
- Comparative drug screening in NUT midline carcinoma
- (2014) A H Beesley et al. BRITISH JOURNAL OF CANCER
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Activation of SOX2 Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma
- (2014) R. Wang et al. CANCER RESEARCH
- BRD4: A BET(ter) target for the treatment of AML?
- (2014) Peter Valent et al. CELL CYCLE
- BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos
- (2014) W Liu et al. CELL DEATH AND DIFFERENTIATION
- Mechanistic Analysis of the Role of Bromodomain-containing Protein 4 (BRD4) in BRD4-NUT Oncoprotein-induced Transcriptional Activation
- (2014) Ranran Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia
- (2014) M-P Garcia-Cuellar et al. LEUKEMIA
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
- (2014) Birgit Knoechel et al. NATURE GENETICS
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- Leukemic Stem Cells: A Review
- (2013) J. A. O'Brien et al. CANCER INVESTIGATION
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
- (2013) A R Grayson et al. ONCOGENE
- A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells
- (2013) Xiao-ning Gao et al. PLoS One
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-order Chromatin Structure
- (2012) Ranran Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation
- (2012) Ballachanda N. Devaiah et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition
- (2012) Nadine Czudnochowski et al. Nature Communications
- Pathogenesis of NUT Midline Carcinoma
- (2011) Christopher A. French Annual Review of Pathology-Mechanisms of Disease
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Perturbation of BRD4 Protein Function by BRD4-NUT Protein Abrogates Cellular Differentiation in NUT Midline Carcinoma
- (2011) Junpeng Yan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
- (2011) Jürgen Cox et al. JOURNAL OF PROTEOME RESEARCH
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
- (2011) G Polier et al. Cell Death & Disease
- Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains
- (2010) Nicolas Reynoird et al. EMBO JOURNAL
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Abrogation of the Brd4-Positive Transcription Elongation Factor b Complex by Papillomavirus E2 Protein Contributes to Viral Oncogene Repression
- (2009) J. Yan et al. JOURNAL OF VIROLOGY
- Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE
- (2009) Eiji Kinoshita et al. Nature Protocols
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
- (2008) Jürgen Cox et al. NATURE BIOTECHNOLOGY
- A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
- (2008) Alessia Montagnoli et al. Nature Chemical Biology
- The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry
- (2008) Judit Villén et al. Nature Protocols
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started